rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Stellate Ganglion Block
Status: Not yet recruiting

The purpose of this study is to determine if the addition of an ultrasound guided left sided stellate ganglion block with bupivacaine in patients undergoing esophagectomy, pneumonectomy, or lobectomy will result in lower rates of postoperative atrial fibrillation as compared to standard of care.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients undergoing esophagectomy, pneumonectomy, or lobectomy aged 18-85.  Exclusion Criteria:  Patients who have an exclusion to regional anesthesia. Patients who have exclusion to stellate blockade. Patients who are pregnant assessed via self-report or pregnancy test if they have taken one - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 85 Years - StdAgeList: Adult, Older Adult
Activity and Participation in Vestibular Disorders
Status: Recruiting

This study will examine whether impairments and personal factors are associated with activity and participation in people with vestibulopathy. Data collection will occur prior to starting vestibular rehabilitation and after completing vestibular rehabilitation.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  - 18-years and older with symptomatic complaints of dizziness and/or imbalance and a medical diagnosis of unilateral vestibular hypofunction  Exclusion Criteria:  1. Cognition <18 on MoCA 2. Visual acuity worse than 20/40 with corrected lenses 3. Loss of protective distal sensation (defined as the inability to feel a 4.31 size monofilament on the plantar surface of the foot) 4. Inability to engage in community mobility - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 100 Years - StdAgeList: Adult, Older Adult
Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
Status: Not yet recruiting

The investigators will evaluate the immune response of immunocompromised adults, who have previously received at least 1 dose of 23-valent pneumococcal polysaccharide vaccine, to the booster series of 15-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine 8 weeks later. Immune response will be assessed by opsonophagocytic assay reactivity and IgG Geometric mean concentration changes.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Subject meets the CDC definition of an immunocompromising condition  o chronic renal failure, congenital or acquired asplenia, generalized malignancy, HIV infection, Hodgkin disease, iatrogenic immunosuppression, leukemia, lymphoma, multiple myeloma, nephrotic syndrome, sickle cell disease or other hemoglobinopathies, and solid organ transplant.  Have received at least 1 dose of PPSV23  Exclusion Criteria:  Less than 5 years since last receipt of PPSV23 validated to patient medical record and Immunize Nevada Website Previous administration of PCV20 Previous administration of PCV13 Less than 14 days since administration of any COVID19 vaccination Previous history of Invasive Pneumococcal Disease (IPD) Antibiotic treatment within the previous 90 days - HealthyVolunteers: No - Gender: All - StdAgeList: Child, Adult, Older Adult
Clinical Decision Support to Improve System Naloxone Co-prescribing
Status: Not yet recruiting

The objective of this study is to evaluate the impact of a clinical decision support (CDS) alert to facilitate the co-prescribing of naloxone, an opioid overdose reversal agent, with high-risk opioid prescriptions. Prescribing naloxone with opioids is a best practice described in the 2022 US Center for Disease Control and Prevention (CDC) guidelines on opioid prescribing. The CDS can improve quality of care delivered by improving compliance with the guideline defined best practices. The project will compare CDS alert facilitated co-prescribing of naloxone with high-risk opioid prescriptions vs usual care to evaluate the effectiveness of the CDS alert for improving naloxone prescribing. The patients are not assigned to an intervention and will be receiving any changes in care as part of their routine medical care, rather than a specific intervention that is distinct from their usual medical care. The researchers hypothesize that the CDS alert will be acceptable to providers while increasing naloxone co-prescribing which will reduce the number of opioid overdoses in subsequent 6 months.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients receiving an opioid prescription at discharge from inpatient/ED or close visit in outpatient settings where the clinical decision support (CDS) is implemented  Exclusion Criteria:  Patients <12 and >89 year of age Cancer diagnosis Hospice care/palliative care Sickle cell disease diagnosis Patients who arrived in error Patients who were triaged to obstetrics - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 12 Years - MaximumAge: 89 Years - StdAgeList: Child, Adult, Older Adult - StudyPopulation: Residents and visitors to the state of Colorado who seek healthcare within the University of Colorado Health (UCHealth) system. - SamplingMethod: Non-Probability Sample
Rapid Diagnosis of Viral Acute Respiratory Infection to Decrease Unnecessary Antibiotic Utilization in the Emergency Department (RADIATE)
Status: Not yet recruiting

The study titled " The Effect of Definitive Identification of Viral Etiology in Emergency Department Patients with Acute Respiratory Infection on Antibiotic Utilization (RADIATE)" aims to investigate the effectiveness of a rapid diagnostic approach in reducing unnecessary antibiotic use in the emergency department (ED) for patients presenting with acute respiratory illness (ARI) due to a virus. Using a prospective design, eligible participants are individuals who visit the ED with complaints related to acute respiratory illness. The study will employ a single-arm consecutive enrollment approach. The intervention involves the implementation of a rapid point-of-care multiplex polymerase chain reaction (PCR) test to promptly identify the viral cause of the infection. By utilizing a rapid diagnostic tool to identify viral etiology, the study aims to provide healthcare professionals in the ED with more accurate information to guide treatment decisions. Ultimately, the goal is to decrease the unnecessary use of antibiotics for ARI's due to a virus, which has several negative outcomes including promotion of antibiotic resistance, exacerbating ED length of stay and encouraging unnecessary additional diagnostic tests.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Over the age of 18 Clinical suspicion of an acute respiratory infection by an emergency department provider Patient endorses at least ONE symptom of respiratory illness including: cough, sneezing, runny or stuffy nose, sore throat, headaches, muscle aches, trouble breathing, shortness of breath, fever Patient reports symptoms lasting less than 14 days (i.e., no chronic symptoms) Patient able to provide informed consent  Exclusion Criteria:  Patient is a prisoner or ward of state Patients that will get antibiotics regardless of of the results of the test (e.g. sepsis, hypoxia, shock, lobar pneumonia, altered mental status, meningitis, pyelonephritis, appendicitis or related, high clinical severity not otherwise specified Patients who have tested positive for C. diff in the last 60 days Patients who are hospitalized from the emergency department Patients that have an oxygen saturation lower than 95% at triage Altered mental status - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Impact of Bluetooth Haptics Device Distraction on Mechanical Pain Thresholds Induced by PinPrick Stimulators
Status: Not yet recruiting

This is a prospective, crossover study of healthy participants evaluating the mechanical pain threshold for weighted pinprick stimuli.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Greater than 18 years of age English speaking Hearing intact  Exclusion Criteria:  History of chronic pain or acute pain syndromes Currently has nausea Has hearing loss Is pregnant Is currently taking beta blockers, chronotropic heart medications, or opioids or other prescription pain medications - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 99 Years - StdAgeList: Adult, Older Adult
Evaluation of the Efficiency and Economic Impact of LC-OCT (Line-field Confocal Optical Coherence Tomography) for the Diagnosis and Management of Basal Cell Carcinomas
Status: Not yet recruiting

This is a comparative, randomized, prospective, multicenter clinical investigation aimed at evaluating the efficiency and economic impact of LC-OCT (Line-field Confocal Optical Coherence Tomography) for the diagnosis and management of basal cell carcinomas.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patient with one or more clinically suspicious lesions of BCC for which:  The diagnosis is uncertain following clinical and dermoscopic examination, and diagnostic biopsy is necessary according to the latest European guidelines from EADO. And/or for which the knowledge of the histological subtype determines the subsequent management. And/or for which diagnostic biopsy is necessary in the standard practice to confirm the clinical diagnosis (peri-orificial facial lesions, any lesion that may require complex surgical reconstruction).  Exclusion Criteria:  The lesion is suspected to be a recurrent BCC. The suspicious lesion has been previously treated by other surgical or non-surgical methods (cryotherapy, topical treatment, PDT, etc.). Lesions within 3 cm of the eye. Presence of cutaneous comorbidities that could interfere with a proper evaluation of the studied lesion according to the investigator. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
Status: Not yet recruiting

AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMobile 6L, and KardiaMobile Card have FDA clearance for ECG rhythm recording. A modified single-lead Kardia smartphone 12-lead ECG was previously validated in the multicenter ST LEUIS study for the diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI).

Recently, AliveCor developed a new device: AliveCor (AC) 12-lead (12L) ECG System to record simultaneously 4 leads of ECG and then generate complete 12-lead ECGs. A previous protocol at the University of Oklahoma involved 200 subjects with early prototypes of the AC 12L device with the specific aim to validate that it accurately generated 12-lead ECGs as compared to simultaneously acquired FDA-cleared 12-lead ECGs. The prototype version of the AliveCor 12L ECG System simultaneously measured four channels of ECG (leads I, II, V2, V4), calculated the remaining limb leads as is standard for 12-lead ECGs (Leads III, aVR, aVL, aVF) and synthesized the remaining 4 precordial ECG leads (V1, V3, V5, V6). This protocol will serve to validate the production version of the system against standard 12-Lead ECGs for the diagnosis of STEMI and NSTEMI in patients admitted to the Emergency Department or directly to the Cardiac Cath Lab for the evaluation of chest pain. It is anticipated that the waveforms for each of the 12 leads from the AC 12L ECG System will be highly correlated with the corresponding leads from the comparator commercially available 12-lead ECG devices used at participating sites. The purpose of this study is to clinically validate that the four-channel AC 12L ECG device can enable the diagnosis of STEMI and NSTEMI in a non-inferior manner to existing 12-lead ECG devices.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Male or female > 18 years of age. Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures. Symptoms of chest pain upon presentation at the Emergency Department of the participating institution.  Exclusion Criteria:  Inability or refusal of the patient and/or the patient's legally acceptable representative to provide written informed consent for any reason. Other conditions that in the opinion of the Lead Investigator may increase risk to the subject and/or compromise the quality of the clinical trial. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Effectiveness of Topical Magnetite Zinc Oxide Composite Nanoparticles in the Management of Oral Potentially Malignant Lesions
Status: Recruiting

ZnO nanoparticles are now being widely researched for their anticancer properties. They show relatively high biocompatibility. They also show selective cytotoxicity against cancerous cells in in vitro condition compared with other nanoparticles. They can be further surface engineered to show increased selective cytotoxicity. The synthesis process of ZnO nanoparticles is relatively easy, with a wide variety of methods. Owing to these different methods of synthesis, their size and size distribution can be easily controlled. One of the novel methods of synthesis of ZnO is Magnetite ZnO-Fe3O4 Composite Nanoparticles.Magnetite ZnO-Fe3O4 conjugated NPs retained inherent selective property of ZnO and magnetic property of Fe3O4 NPs and showed preferential cytotoxicity towards breast cancer cell line MDA-MB-231, with no significant cytotoxicity towards noncancerous Mouse Fibroblast NIH 3T3 cell.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Both genders ranged from 25 to 60 years. Clinically confirmed OPMLs: the clinical picture of oral erythroplakia includes well-demarcated red discs with a smooth or granular surface, leukoplakia is classified into four clinical types: type I, a flat white patch or plaque without red components; type II, a flat white patch or plaque with red components; type III, a slightly raised or elevated white plaque; and type IV, a markedly raised or elevated white plaque. Histopathological confirmed OPMLs with low or moderate dysplasia  Exclusion Criteria:  Presence of systemic conditions as serious active or recurrent infections, malignancy, diabetes mellitus, hypertension, or significant heart, liver, or renal diseases. Assessed using a medical questionnaire guided by Cornell Medical Index Smoking 6 weeks before the clinical trial Known hypersensitivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation as mentioned in history. Pregnancy or breastfeeding. Histological diagnosis of severe, or invasive oral squamous cell carcinoma. Vulnerable groups (Handicapped, orphans or prisoners). Any lesion less than 1 cm in diameter. - HealthyVolunteers: No - Gender: All - MinimumAge: 25 Years - MaximumAge: 60 Years - StdAgeList: Adult
Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy
Status: Not yet recruiting

The goal of the clinical trial is to find out whether transdermal estradiol will reduce the adverse effects of androgen deprivation therapy in prostate cancer patients.

The primary aim of this study is to estimate the efficacy of transdermal estradiol (E2) in reducing androgen deprivation therapy induced adverse effects on sexual function. A secondary aim of this study is to estimate the utility of E2 and the combination of E2 with supervised exercise in reducing other androgen deprivation therapy related adverse effects.

Participants (n=310) will use transdermal estradiol for 12 months concomitant to androgen deprivation therapy. The use of transdermal estradiol will start at the beginning of the trial, at the same time as androgen deprivation therapy. A subgroup of participants (n=120) will also be allocated to perform six months supervised resistance training.

Researchers will compare transdermal estradiol group to control group, and resistance training groups and non-training control groups.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Men with localized prostate cancer, and scheduled for external beam radiation with adjuvant subcutaneous androgen deprivation therapy, leuprorelin (LHRH agonist) for at least 12 months without any other endocrinology treatments for prostate cancer Adults (age over 18 years) Sufficient performance status (Eastern Cooperative Oncology Group, 0-1) Body mass index between 18.5 - 30.0 Willingness to participate and signed consent  Exclusion Criteria:  Patients with low-risk prostate cancer (ISUP Gleason grade 1) Patients with expected adjuvant androgen deprivation therapy for less than one year Distant bone, lymph node, or soft tissue metastasis Cardiac pacemaker Prior recent cardiovascular event or stroke (<12 months) Past or current venous thromboembolism Other untreated or unstable malignancy in risk of recurrence/progression (as judged by the treating physician) Concurrent glucocorticoid treatment Physical disabilities for regular exercise Any medication or condition considered as a contraindication to estradiol (allergy to adjuvant compounds (carbomer, trolamine), history with thromboembolic disorders (protein C, protein S, or antithrombin deficiency), porphyria, acute or previous liver disease, drugs with cytochrome P450 enzyme metabolism (anticonvulsants: phenobarbital, phenytoin, carbamazepine; anti-infectives: rifampicin, rifapentine, nevirapine, efavirenz; and St. John's wort)) or leuprorelin (allergy to adjuvant compounds (polylactic acid), Qt-time prolonging drugs (quinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide, methadone, moxifloxacin, antipsychotics) Known allergy to estradiol or leuprorelin Expected poor compliance or expected survival time of less than one year - HealthyVolunteers: No - Gender: Male - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome
Status: Not yet recruiting

The objective of this randomized, double-blind, placebo-controlled study is to evaluate the effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency, improving quality of life, and addressing psychological distress in individuals diagnosed with irritable bowel syndrome (IBS), as compared to those who receive no intervention.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  IBS diagnosed using the Rome IV criteria Age above 18 years old and any gender Any subtypes of IBS (diarrhea, constipation or mixed)  Exclusion Criteria:  Presence of red flag symptoms (weight loss, anemia, night symptoms, abdominal mass, strong family history of cancer) Was prescribed antibiotic (s) within the past one month Medical conditions that contraindicate probiotic use including severe sepsis and pregnancy Presence of bowel malignancy Diagnosis of bowel infection within the past one month Previous abdominal surgeries Patients with overt psychiatric illnesses including schizophrenia and manic disorders A history of allergy to probiotic Was prescribed probiotic (s) within the past one month Was previously prescribed probiotic Skal Pro™ (LP299V™) - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Effect of Cupping Therapy on Nitric Oxide Level in Patients With Cervical Spondylosis
Status: Not yet recruiting

this study will be conducted to investigate the effect of cupping therapy on the nitric oxide level in patients with cervical spondylosis

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients with (cervical spondylosis) from both sexes. Age range (24-60) in chronic stages. BMI from20-25 kg/m2.  Exclusion Criteria:  Renal and hepatic patients. Anemia, hepatic disease, and dermatological diseases. Morbid obese patients if their BMI exceeds the 25 kg/m2 will be also excluded. the patients are taking any medications known to affect the pain level The patients have a systemic illness, dermatological problems, skin allergy, local ischemic problems - HealthyVolunteers: No - Gender: All - MinimumAge: 24 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
A Study of Participants With β-Thalassemia Treated With Betibeglogene Autotemcel
Status: Recruiting

The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Participant must be treated with beti-cel in the post marketing setting at a center in the US that participates in the Registry. Participant must sign an informed consent and/or assent prior to enrollment as required under applicable laws and regulations. Participant must have signed an informed consent and/or assent permitting data to be shared with Center for International Blood and Marrow Transplant Research (CIBMTR). Participant must be followed by a hematologist based in the US.  Exclusion Criteria:  - There are no exclusion criteria for Registry participation. - HealthyVolunteers: No - Gender: All - StdAgeList: Child, Adult, Older Adult - StudyPopulation: Participants with β-thalassemia treated with beti-cel in the post marketing setting at a center in the United States (US) that participates in the Registry. - SamplingMethod: Non-Probability Sample
Pregabalin in Treatment of Postdural Puncture Headache
Status: Not yet recruiting

Lumbar puncture (LP), often known as a "spinal tap," is a standard medical technique pioneered in the late 1900s by Heinrich Quincke. It involves the retrieval and analysis of cerebrospinal fluid (CSF) from the spinal cord, serving as the benchmark for diagnosing conditions like subarachnoid hemorrhage, meningitis, and specific neurological conditions. Pregabalin, an anticonvulsant medicine that blocks calcium entry, is used to treat a variety of diseases. It has been used to relieve pain in a variety of patient groups, including those with chronic pain, epilepsy, and anxiety disorders

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  age from 21 to 65 years old, both genders, confirmed diagnosis of postdural puncture headache (PDPH)  Exclusion Criteria:  patient refusal known allergy to the drug used in the study patients with a history of convulsions chronic headaches contraindications to regional anesthesia (such as local infection and coagulation abnormalities). Clinical indications of elevated intracranial pressure or associated risk factors Deteriorated patients - HealthyVolunteers: No - Gender: All - MinimumAge: 21 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult